1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Institutional Development Award (IDeA) program supports biomedical research capacity building in states that have historically received low levels of NIH funding. The Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) Notice of Funding Opportunity (NOFO) supports the expansion and sustainability of biomedical research centers in IDeA-eligible institutions. These centers will focus on building research capacity in broad scientific areas of strategic importance for the institutions. The goal of COBRE-E is to expand research capacity by growing the institutional faculty base and supporting research projects and core facilities in the new area. The objective of COBRE-S is to sustain the infrastructure by continuing the growth of the faculty base and consolidating research cores. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.
Funding Opportunity Number: PAR-27-055. Assistance Listing: 93.859. Funding Instrument: G. Category: HL.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligibility is restricted to institutions that meet all the following criteria:In an IDeA-eligible state, commonwealth, or jurisdiction, which are Alaska, Arkansas, Delaware, Hawaii, Idaho, Kansas, Kentucky, Louisiana, Maine, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Puerto Rico, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, and Wyoming; andAward doctoral degrees in health-related sciences or are independent biomedical research institutes/medical centers with ongoing biomedical research programs funded by the NIH or other federal agencies; andHold three or fewer active COBRE awards (except for COBRE Phase 3), including those in no-cost extension at the time of application submission. Applications will not be accepted from organizations that hold four or more active Phase 1, Phase 2, COBRE-D, COBRE-E, and COBRE-S awards, including those in no-cost extension.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Confirm the full requirements in the official notice before applying.
Applications for Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed) are due May 25, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in 24 states, including Alaska, Arkansas, Delaware, Hawaii, and Idaho. Check the official notice for the full list.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Quantum Benchmarking Initiative Phase B is a grant from DARPA that funds rigorous research and development planning by advanced quantum computing companies working toward utility-scale quantum operation. Selected through a competitive multi-stage evaluation process, Phase B participants spend one year developing detailed R&D plans, identifying technical risks, and specifying risk-reduction prototypes for fault-tolerant quantum computers. The program aims to verify whether any quantum computing approach can achieve computational value exceeding its cost by 2033. Awards range from $1 million to $5 million. Eligibility is currently limited to the 11 companies already selected for Stage B, though new entrants may apply to Stage A via DARPA-PA-26-02-02 by September 30, 2026.
The Enveda CASMI 2026 competition on Kaggle is the 2026 Critical Assessment of Small Molecule Identification challenge. It launched on 14 September 2026 and is sponsored by Enveda Therapeutics. Entrants build machine-learning models that predict 2D chemical structures, as SMILES strings, from LC-MS/MS tandem mass spectra of natural products in complex biological extracts. Models must handle both known and novel molecules, going beyond spectral library matching. The stated applications are drug discovery and finding disease biomarkers. The $50,000 prize pool pays $16,000, $12,000, $9,000, $7,000 and $6,000 to the top five teams. Winning solutions are released under the MIT licence, and the data is limited to competition and non-commercial academic use under CC BY-NC 4.0. The entry deadline is 7 December 2026, and final submissions are due 14 December 2026 at 11:59 PM UTC.
NIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read article